





Passive Diffusion










## Bioavailability

Examples of <100% Availability

- Incomplete absorption
- Decomposition
- First-pass metabolic inactivation
- Poor transport

$$\text{Absolute bioavailability (F)} = \frac{AUC_{po}}{AUC_{iv}} \times \frac{Dose_{iv}}{Dose_{po}} \times 100$$







**Bioavailability**

$$\text{Relative bioavailability (F)} = \frac{AUC_{po}(\text{test})}{AUC_{po}(\text{std})} \times \frac{Dose_{po}(\text{std})}{Dose_{po}(\text{test})} \times 100$$

Method of Entry:

1. Pulmonary (High Surface area – Many Capillaries)
2. Gastrointestinal
3. Dermal
4. IV
5. Muscle Injection






Tarjei Rygnestad, MD, PhD.

Consultant, Department of Anaesthesia and Intensive Care, The University Hospital in Trondheim and Professor in Clinical Pharmacology, The Norwegian University of Science and Technology, Trondheim, Norway

Cocaine (Metabolism of Major Illicit Drugs) (Human Drug Metabolism)  
<http://what-when-how.com/human-drug-metabolism/cocaine-metabolism-of-major-illicit-drugs-human-drug-metabolism/>



Cocaine metabolism, showing the role of CYP3A4 in demethylation (toxic pathway) and human carboxylesterases (hCE-1 and 2) and butyrylcholinesterase (BChE). Esterases are found in virtually every tissue, clearing cocaine extremely rapidly.

Drug	Dose (mg)	half-life (h)	Bioavailability			Source
			Nasal	Smoking	Oral	
Heroin		0.1				NHTSA
Acetylsalicylic Acid		0.25				PfC
GHB	2000-4000	0.5				NHTSA
Cocaine	40-100	0.8	57%	70%		NHTSA
Morphine	5-30	1.9				30% PfC
Acetaminophen		2				PfC
Ketamine		2.3	40%			20% NHTSA
LSD		3				NHTSA
Oxycodone	2.5-30	5				NDAAs
MDMA		7				NHTSA
Caffeine		8				NDAAs
Methamphetamines	2.5-15	10.1				NHTSA
PCP		21		50%		NHTSA
Methadone	20-200	40				75% NHTSA
Diazepam	4-40	43				99% NHTSA
THC	2.5-10	72				NHTSA
Phenobarbital		100				NDAAs

Clearance:

$$CL_{system} = CL_{renal} + CL_{hepatic} + CL_{excretion} + CL_{other}$$

$$CL_{renal} = \frac{C_{urinary} * V_{urinary}}{C_{plasma}}$$




FIG. 1.—A schematic representation of the concentration-clearance relationship.

Benet, L.Z.; Zia-Amirhosseini, P., "Basic Principles of Pharmacokinetics", *Toxicologic Pathology*, 23 (1995) 115-123.

What makes a good drug candidate:

RO5 – Rule of Five – Lipinski's Rule of Five

1. No more than 5 H-bond donors
2. No more than 10 H-bond acceptors
3. <500 amu molecular mass
4. Octanol:H<sub>2</sub>O partition coefficient < 5

Modified Rules:

1. Octanol:H<sub>2</sub>O partition coefficient  $-0.04 < P < +5.6$
2. Molar Refractivity from 40 to 130
3. Polar Surface Area < 140 Å<sup>2</sup>
4. 10 or fewer Rotatable Bonds

